Ovarian Rejuvenation Treatments Show Promise But Lack Clinical Proof

Female fertility declines with age due to ovarian aging, driven by depletion of egg-containing follicles and changes in the ovarian environment. This has sparked interest in interventions that might slow or reverse this process, potentially extending reproductive lifespan.

Researchers reviewed evidence for popular ovarian rejuvenation treatments including platelet-rich plasma injections, autologous stem cell therapies, and mitochondrial transfer. These approaches are based on sound biological theories and have gained commercial attention despite limited clinical data.

While these interventions often improve surrogate markers like anti-Müllerian hormone levels and antral follicle counts in early studies, the review found no consistent evidence they translate into better embryo quality, chromosomally normal embryos, or increased live birth rates. The distinction between temporary follicle activation and true modification of reproductive aging remains unclear.

The authors integrated findings with emerging research on aging biology, including nutrient-sensing pathways and epigenetic reprogramming. They noted that ovarian fibrosis may represent a modifiable target for preserving ovarian function.

Safety data remain limited, with potential procedural and infectious risks requiring careful consideration. The researchers conclude that routine clinical use of these interventions is premature, calling for standardized protocols, adequately powered randomized trials with live birth endpoints, and rigorous safety assessments before widespread adoption.